04:54 AM EST, 12/09/2024 (MT Newswires) -- Merck & Co. ( MRK ) said Sunday that its phase 2 waveLINE-007 trial evaluating zilovertamab vedotin, its investigational antibody-drug conjugate in combination with R-CHP for the treatment of patients with previously untreated diffuse large B-cell lymphoma, achieved a 100% complete response rate.

Patients were treated with the drug at 1.75 mg/kg, which has been established as the recommended phase 3 dosage, the company said.